Home page photo

Taking cellular immunotherapy to the next level

We are focused on the development of stem cell-derived Natural Killer cells (NK cells) as a medicinal asset in the fight against cancer. NK cells are the new star in the domain of cellular immunotherapy, due to their tightly regulated “natural killing” of cancer cells; they play an important role in control and even cure of both solid and hematological malignancies, like acute myeloid leukemia (AML) and multiple myeloma (MM).

blue_cell

Pioneering, developing and manufacturing

Over the last decade we studied the role of NK cells in cancer treatment extensively and pioneered, developed and optimized our in-house NK-cell production processes.During our phase I safety study we verified our lead product oNKord® (naked NK cells) to be a safe therapeutic agent in the field of cellular immunotherapy. Currently we are developing our second product: Chimeric Antigen Receptor (CAR)-engineered NK cells. A growing number of commercial and academic partners have chosen Glycostem because of our expertise with NK cells and their production.

Our latest news

Glycostem initiates phase I/IIa trial of oNKord® in patients with Acute Myeloid Leukemia

20th November 2020 – Glycostem today announced the opening of a phase I/IIa trial for its lead product oNKord® for the treatment of AML patients. The WiNK trial will enroll 33 AML patients at eight clinical sites based in five European countries.

FDA grants Glycostem’s oNKord® Orphan Drug Designation for Multiple Myeloma

12th October 2020 - Glycostem announces it has received the FDA’s Orphan Drug Designation (ODD) for treatment of Multiple Myeloma (MM) patients with its investigational product oNKord®.

Glycostem collaborates with LUMICKS

30th July, 2020 - Glycostem collaborates with LUMICKS to improve immunotherapeutic drug development. By quantifying binding strength between immune and cancer cells using the unique z-Movi® Cell Avidity Analyzer, Glycostem exploits the predictiveness of avidity in finding the best NK-cell population for cellular therapy.